WO2025137345 - CRYSTALLINE FORMS OF AN IMIDAZOPYRIDINE DERIVATIVE
National phase entry is expected:
Publication Number
WO/2025/137345
Publication Date
26.06.2025
International Application No.
PCT/US2024/061121
International Filing Date
19.12.2024
Title **
[English]
CRYSTALLINE FORMS OF AN IMIDAZOPYRIDINE DERIVATIVE
[French]
FORMES CRISTALLINES D'UN DÉRIVÉ D'IMIDAZOPYRIDINE
Applicants **
ARISAN THERAPEUTICS INC.
Inventors
GANTLA, Vidyasagar Reddy
BROWN, Eric
SOKOLOVA, Nadezda V.
MCCORMACK, Kenneth
HENKEL, Gregory
Priority Data
63/612,863
20.12.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2927 | |
| EPO | Filing, Examination, Granting | 18322 | |
| Japan | Filing, Examination, Granting | 2431 | |
| South Korea | Filing, Examination, Granting | 2728 | |
| USA | Filing, Examination, Granting | 8560 |
Total:
34,968
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Polymorphic forms A, B, C, D, E, and F of Compound 1, as shown below, have been discovered and formulated with pharmaceutically acceptable excipients to form tablets and capsules.[French]
Des formes polymorphes A, B, C, D, E et F du composé 1, telles que représentées ci-dessous, ont été découvertes et formulées avec des excipients pharmaceutiquement acceptables afin de former des comprimés et des capsules.